Moneycontrol PRO
UPCOMING EVENT:Are you 45+? Planning for retirement? We have just the right webinar for you - Planning for Retirement with Life Insurance on 27-Jan, 3pm. Register now!
you are here: HomeNewsBusiness

Tata Group, Singapore Airlines infuse Rs 585 crore in Vistara: Report

The infusion is for maintaining liquidity, covering fixed costs and making payments to lesser,

November 23, 2020 / 02:40 PM IST

Promoters Tata group (51 percent owner) and Singapore Airlines (49 percent owner) have invested Rs 585 crore to keep Vistara afloat amid the COVID-19 pandemic – in what is their second-highest equity infusion in a year in the airline.

The Rs 585 crore capital for FY21 was through purchase of shares in a rights issue, The Economic Times reported.

Moneycontrol could not independently verify the report.

Overall, shareholders have pumped three tranches of infusions (first in April of Rs 500 crore and second in July of Rs 750 crore) into the airline since the pandemic shut air travel completely in March – and has only resumed in slow phases. Total investment in the first seven months of FY21 is now Rs 1,835 crore – up from the Rs 1,500 crore in FY20, the report said.

The infusions are for maintaining liquidity, covering fixed costs and making payments to lesser, executives told the paper.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Vinod Kannan, Chief Commercial Officer of Vistara, acknowledged that the pandemic has affected growth plans, but did not comment on the financial information, as per the report.

He added that shareholders “remain committed to the expansion strategy and long-term vision” but there are “many unknowns at this point of time”, adding that much would depend on how soon a vaccine is available and how soon demand returns to pre-COVID levels.

For FY20 Vistara had cash and carry equivalents of Rs 700 crore and has accumulated losses of more than Rs 4,400 crore since it began operations. The pandemic has likely widened losses, the company added.
Moneycontrol News

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark